Syntara commences dosing in phase 2 myelofibrosis trial of its pan-LOX inhibitor

December 13, 2023 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Clinical-stage drug development company Syntara (ASX:SNT), formerly Pharmaxis, has commenced dosing in the final cohort of a phase 2 clinical trial studying its pan-LOX inhibitor SNT-5505 in patients with myelofibrosis. …

Subscribe now to continue reading.

Latest Video

Given the official use of AI, a cease and desist would not be unreasonable
September 22, 2026 - Latest News
Telix announces takeover of ITM to create a global radiopharmaceutical powerhouse
September 21, 2026 - Australian Biotech
Officials are using AI to create efficiencies in the HTA evaluation process
September 21, 2026 - Latest News
New AI contribution tool delivers 150 patient voices to the PBAC
September 21, 2026 - Latest News
Treasury has moved on from the PBS, but the policies built on its error have not
September 21, 2026 - Latest News

Syntara commences dosing in phase 2 myelofibrosis trial of its pan-LOX inhibitor

This is a preview of subscriber content

Latest Video

Most Read

Given the official use of AI, a cease and desist would not be unreasonable

Telix announces takeover of ITM to create a global radiopharmaceutical powerhouse

Officials are using AI to create efficiencies in the HTA evaluation process

New AI contribution tool delivers 150 patient voices to the PBAC

Treasury has moved on from the PBS, but the policies built on its error have not

New Stories

Medicines Australia seeks answers on AI in HTA process

The prevention gap and inside Sally Panton's bet on cellular health

Pfizer 'deeply disappointed' in response to PBAC refusing to move on price

Lilly goes direct with a patient platform for its non-PBS medicines

A 'multistakeholder' reference group to shadow agreement negotiations

If there is a productivity gain in the process, then it should be passed on

Given the official use of AI, a cease and desist would not be unreasonable

Sign In

Syntara commences dosing in phase 2 myelofibrosis trial of its pan-LOX inhibitor

This is a preview of subscriber content

Latest Video

Most Read

Given the official use of AI, a cease and desist would not be unreasonable

Telix announces takeover of ITM to create a global radiopharmaceutical powerhouse

Officials are using AI to create efficiencies in the HTA evaluation process

New AI contribution tool delivers 150 patient voices to the PBAC

Treasury has moved on from the PBS, but the policies built on its error have not

Follow Us

New Stories

Medicines Australia seeks answers on AI in HTA process

The prevention gap and inside Sally Panton's bet on cellular health

Pfizer 'deeply disappointed' in response to PBAC refusing to move on price

Lilly goes direct with a patient platform for its non-PBS medicines

A 'multistakeholder' reference group to shadow agreement negotiations

If there is a productivity gain in the process, then it should be passed on

Given the official use of AI, a cease and desist would not be unreasonable